A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

REFERENCES

• Jemal A., Murray T., Ward E., Samuels A., Tiwari R. C., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Vokes E. E., Weichselbaum R. R., Lippman S. M., Hong W. K. Head and neck cancer. N. Engl. J. Med. 1993; 328: 184–194
   PubMed Web of Science ®Google Scholar
• Laramore G. E., Scott C. B., al-Sarraf M., Haselow R. E., Ervin T. J., et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 705–713
   PubMed Web of Science ®Google Scholar
• Cooper J. S., Pajak T. F., Forastiere A., Jacobs J., Fu K. K., Ang K. K., Laramore G. E., Al-Sarraf M. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?. Head Neck 1998; 20: 588–594
   PubMed Web of Science ®Google Scholar
• Vokes E., Weichselbaum R., Lippman S., Hong W. Head and neck cancer. N. Engl. J. Med. 1993; 328: 184–194
   PubMed Web of Science ®Google Scholar
• Vokes E. E., Weichselbaum R. R. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J. Clin. Oncol. 1990; 8: 911–934
   PubMed Web of Science ®Google Scholar
• Vokes E., Beckett M., Karrison T., Weichselbaum R. The interaction of 5-fluorouracil hydroxyurea and radiation in two human head and neck cancer cell lines. Oncology 1992; 49: 454–460
   PubMed Web of Science ®Google Scholar
• Moran R., Danenberg P., Heidelberger C. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem. Pharmacol. 1982; 31: 2929–2935
   PubMed Web of Science ®Google Scholar
• Vokes E. E., Panje W. R., Schilsky R. L., Mick R., Awan A. M., et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J. Clin. Oncol. 1989; 7: 761–768
   PubMed Web of Science ®Google Scholar
• Wheeler I. R.H., Harris J., Spencer S., Machtay M., Shultz C., Spanos W. J., Rotman R. Meredith R. RTOG 9610: Phase II Study of Reirradiation with Concurrent Hydroxyurea and 5-Fluorouracil in Patients with Recurrent Squamous Cell Cancer of the Head and Neck: Survival Results. Proc. Am. Soc. Clin. Oncol. 2001; 20: A887
   Google Scholar
• Garden A. S., Pajak T. F., Vokes E., Forastiere A., Ridge J., et al. Preliminary data of RTOG 9703—a phase II randomized trial of concurrent radiation and chemotherapy for advanced squamous cell of the head and neck. Proc. Am. Soc. Clin. Oncol. 2001; 20: A891
   Google Scholar
• De Crevoisier R., Domenge C., Wibault P., Koscielny S., Lusinchi A., et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001; 91: 2071–2076
   PubMed Web of Science ®Google Scholar
• Vokes E. E., Stenson K., Rosen F. R., Kies M. S., Rademaker A. W., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 2003; 21: 320–326
   PubMed Web of Science ®Google Scholar
• Haraf D. J., Rosen F. R., Stenson K., Argiris A., Mittal B. B., et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin. Cancer Res. 2003; 9: 5936–5943
   PubMed Web of Science ®Google Scholar
• Haraf D. J., Kies M., Rademaker A. W., Stenson K., Mittal B., et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J. Clin. Oncol. 1999; 17: 638–644
   PubMed Web of Science ®Google Scholar
• Vokes E. E., Stenson K., Rosen F. R., Kies M. S., Rademaker A. W., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 2003; 21: 320–326
   PubMed Web of Science ®Google Scholar
• Vermorken J. B.R.E., Van Herpen C., Germa Lluch J., Stewart S., Gorlia T., Degardin M., Schollen K., Bernier J. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2004; vol. 23
   Google Scholar
• Choy H., DeVore R. F., Hande K. R., Porter L. L., Rosenblatt P. A., et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 2001; 34: 441–449
   PubMed Web of Science ®Google Scholar
• Tishler R. B., Norris C. M., Jr., Colevas A. D., Lamb C. C., Karp D., et al. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002; 95: 1472–1481
   PubMed Web of Science ®Google Scholar
• Koukourakis M. I., Kourousis C., Kamilaki M., Koukouraki S., Giatromanolaki, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur. J. Cancer 1998; 34: 838–844
   PubMed Web of Science ®Google Scholar
• Mauer A. M., Masters G. A., Haraf D. J., Hoffman P. C., Watson S. M., Golomb H. M., Vokes E. E. Phase I study of docetaxel with concomitant thoracic radiation therapy. J. Clin. Oncol. 1998; 16: 159–164
   PubMed Web of Science ®Google Scholar
• Koukourakis M. I., Bahlitzanakis N., Froudarakis M., Giatromanolaki A., Georgoulias V., et al. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non–small–cell lung carcinoma. Br. J. Cancer 1999; 80: 1792–1796
   PubMed Web of Science ®Google Scholar
• Aamdal S. H.M., Tonelli D., Lauvvang G., Owre K., Hatlevoll R. Docetaxel (Taxotere) Combined with Radiation in Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)—A Phase I/II Study. American Society of Clinical Oncology Annual Meeting. 1998; vol 17: 476a
   Google Scholar
• Mudad R., Ramsey M., Kouitz K., Curiel T. J., Hartz R., et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer Feb., 2003; 39(2)173–177
   PubMed Web of Science ®Google Scholar
• Segawa Y., Ueoka H., Kiura K., Moritaka T., Kamei H., et al. A Phase I/II Study of Docetaxel (TXT) and Cisplatin (CDDP) with Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC). American Society of Clinical Oncology Annual Meeting. 2000; vol 19: 508
   Google Scholar
• Milano M. T., Haraf D. J., Stenson K. M., Witt M. E., Eng C., Mittal B. B., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin. Cancer Res. 2004; 10: 4922–4932
   PubMed Web of Science ®Google Scholar
• National_Cancer_Institute. Investigator's handbook: a manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment National Cancer Institute, http://ctepinfonihgov/handbook/defaulthtm Available online at Accessed July 25, 2002
   Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205–216
   PubMed Web of Science ®Google Scholar
• Brookmeyer R., Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29–41
   Web of Science ®Google Scholar
• Forastiere A. A., Metch B., Schuller D. E., Ensley J. F., Hutchins L. F., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 1992; 10: 1245–1251
   PubMed Web of Science ®Google Scholar
• Fountzilas G., Ciuleanu E., Dafni U., Plataniotis G., Kalogera-Fountzila A., et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med. Oncol. 2004; 21: 95–107
   PubMed Web of Science ®Google Scholar
• Homma A., Shirato H., Furuta Y., Nishioka T., Oridate N., et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J 2004; 10: 326–332
   PubMed Web of Science ®Google Scholar
• Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• Groen H., Schramel F. M., Van der Hoeven J. J.M., Termeer R., Smit H. J., et al. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter phase III trial. Proc. Am. Soc. Clin. Oncol. 2003; 22: 623, (Abstr. 2505)
   Google Scholar
• Camps C., Massuti B., Jimenez A., Maestu I., Gomez R. G., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann. Oncol. Mar., 2006; 17(3)467–472
   PubMed Web of Science ®Google Scholar
• Hitt R., Amador M. L., Quintela-Fandino M., Jimeno A., Del Val O., Hernando S., Cortes-Funes H. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 2006; 106: 106–111
   PubMed Web of Science ®Google Scholar
• Posner M. R., Hershock D., Le-Lann L., Devlin P. M., Haddad R. I. Docetaxel added to Induction Therapy in Head and Neck Cancer. ASCO 2006 2006, [Scientific Special Session]
   Google Scholar
• Hitt R., Lopez-Pousa A., Martinez-Trufero J., Escrig V., Carles J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 2005; 23: 8636–8645
   PubMed Web of Science ®Google Scholar
• Posner M. R., Lefebvre J. L. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br. J. Cancer 2003; 88: 11–17
   PubMed Web of Science ®Google Scholar
• Schwartz D. L., Montgomery R. B., Yueh B., Donahue M., Anzai Y., et al. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2005; 103: 2534–2543
   PubMed Web of Science ®Google Scholar
• Mantovani G., Massa E., Astara G., Murgia V., Gramignano G., et al. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes. Oncol. Rep. 2003; 10: 759–766
   PubMed Web of Science ®Google Scholar
• Glisson B. S. The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park) 2002; 16: 83–87
   PubMed Web of Science ®Google Scholar
• Khuri F. R., Shin D. M., Glisson B. S., Lippman S. M., Hong W. K. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin. Oncol. 2000; 27: 25–33
   PubMed Web of Science ®Google Scholar
• Carter D. L., Asmar L., Barrera D., Olsen M., Caracandas J., et al. Two year survival for concurrent carboplatin, paclitaxel, and hyperfractionated radiotherapy in unresectable head and neck cancer. Proc. Am. Soc. Clin. Onco.l 2003; 22: 504, (Abstr. 2028)
   Google Scholar
• Cmelak A. J., Li S., Goldwasser M., Murphy B. A., Adams G. L., Cannon M., et al. A Phase II Trial of Chemoradiation (CR) for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx (L) or Oropharynx (OP): A Trial of the Eastern Cooperative Oncology Group (E2399). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; 5509, Vol. 23, No. 16S, Part I and II (June 1 Supplement)
   Google Scholar
• Machtay M., Rosenthal D. I., Hershock D., Jones H., Williamson S., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J. Clin. Oncol. 2002; 20: 3964–3971
   PubMed Web of Science ®Google Scholar